Last reviewed · How we verify

NCT05746611

Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein

Completed Phase 4 Last updated 19 September 2024
What this trial tests

Phase 4 trial testing Recombinant Mycobacterium tuberculosis fusion protein for injection in Latent Tuberculosis Infection in 7,500 participants. Completed in 13 May 2024.

Timeline
17 April 2023
Primary endpoint
13 May 2024
13 May 2024

Quick facts

Lead sponsorAnhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposediagnostic
Enrollment7,500
Start date17 April 2023
Primary completion13 May 2024
Estimated completion13 May 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — full company profile →

Who can join

6 Months and older, any sex, with Latent Tuberculosis Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients. Cohort I was injected with EC and TB-PPD in both arms, and cohort II was injected with EC only

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase 4 Clinical Trial.
    Chen J, Zhao L, Zhou X, Mo Y, et al · · 2025 · cited 1× · PMID 40560769 · DOI 10.1093/infdis/jiaf332

Verify or expand the search:

Other recruiting trials for Latent Tuberculosis Infection

Currently open trials in the same condition.

Other Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05746611.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing